Prostate Cancer and Prostatic Diseases

• The Role of Caveolin-1 in Prostate Cancer: Clinical Implications Cav-1 is emerging as an important indicator in prostate cancer.
  Prostate Cancer and Prostatic Diseases, March 2010
• Cryoablation of the Prostate: Technical Recommendations Following European guidelines, this is the first paper that establishes the technical recommendations for use of prostate cryotherapy.
  Prostate Cancer and Prostatic Diseases, February 2010
• Preoperative Predictors of Blood Loss at the Time of Radical Prostatectomy The literature contains conflicting data on preoperative predictors of estimated blood loss at radical retropubic prostatectomy. The authors examine the SEARCH database to lend clarity to this issue.
  Prostate Cancer and Prostatic Diseases, January 2010
• Is There a Benefit From Lycopene Supplementation in Prostate Cancer? Lycopene has a chemopreventive effect against prostate cancer, but can it also arrest progression?
  Prostate Cancer and Prostatic Diseases, January 2010
• Primary Care Practices in the Management of Men With Chronic Prostatitis Although studies suggest that CP/CPPS is common, many primary-care physicians reported little or no familiarity, important knowledge deficits and limited experience in managing men with this syndrome.
  Prostate Cancer and Prostatic Diseases, December 2009
• Lymph Node Dissection During Robot-assisted Radical Prostatectomy Since the initial report of robot-assisted laparoscopic prostatectomy in 2001, the technique has gained rapid acceptance and utilization. But how well does this method work for pelvic lymph node dissection?
  Prostate Cancer and Prostatic Diseases, December 2009
• PDE5 Inhibitors for LUTS This review focuses on the relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction, and the role of phosphodiesterase-5 (PDE5) inhibitors for the treatment of LUTS.
  Prostate Cancer and Prostatic Diseases, December 2009
• Clinical Phenotyping in Chronic Prostatitis/Chronic Pelvic Pain Syndrome To aid in the diagnosis and treatment of urologic chronic pain conditions, the authors propose a six-domain phenotype, which can classify these patients clinically and can direct the selection of therapy.
  Prostate Cancer and Prostatic Diseases, June 2009
• 5α-Reductase Inhibitor Treatment of Prostatic Diseases This literature review discusses the theoretical background of 5α-reductase inhibitor (5ARI) treatment for prostatic diseases, and the resulting clinical implications.
  Prostate Cancer and Prostatic Diseases, June 2009
• Repeating an Abnormal Prostate-specific Antigen (PSA) Level Patients with decreased PSA levels may still need a prostate biopsy. Find out why.
  Prostate Cancer and Prostatic Diseases, March 2009
• HIV and Prostate Cancer: A Systematic Review of the Literature Should treatment of prostate cancer be any different in men infected with HIV?
  Prostate Cancer and Prostatic Diseases, March 2009
• Prostate Cancer Chemotherapy in the Era of Targeted Therapy Review recent advances in chemotherapy options for early as well as advanced prostate cancer.
  Prostate Cancer and Prostatic Diseases, March 2009
• Prostate Cancer Stem Cell Therapy: Hype or Hope? The stem cell concept of cancer suggests that each cancer contains a small fraction of stem cells responsible for the maintenance and progression of the disease.
  Prostate Cancer and Prostatic Diseases, December 2008
• Pelvic Lymphadenectomy in Prostate Cancer This review analyzes the anatomy of the prostate gland's lymphatic drainage, and the optimal anatomic extend of pelvic lymph node dissection (PLND).
  Prostate Cancer and Prostatic Diseases, December 2008
• Sweet's Syndrome in Prostate Cancer Originally described in 1964 as an idiopathic dermatosis occurring in women, Sweet's syndrome (acute febrile neutrophilic dermatosis) is associated with malignancy, typically hematological.
  Prostate Cancer and Prostatic Diseases, December 2008
• Prostate Cancer: Genes, Environment, Immunity and the use of Immunotherapy Prostate cancer prevention, the authors of this article argue, may be most effectively based on a closer examination of the environmental and immunity-related triggers for the disease.
  Prostate Cancer and Prostatic Diseases, September 2008
• Prostate Cancer Mortality Rates Compared to Urologist Population Densities This study found that the rate of mortality from prostate cancer was inversely associated with the urologist availability and PSA screening.
  Prostate Cancer and Prostatic Diseases, September 2008
• Beyond Prostate-Specific Antigen: Alternate Serum Markers PSA screening for prostate cancer has well known shortcomings. This article explores the potential usefulness of other existing and future biomarkers, including genetic assays.
  Prostate Cancer and Prostatic Diseases, September 2008
• New Circulating Biomarkers for Prostate Cancer A number of possible new biomarkers for prostate cancer are currently under investigation. This article reviews molecular forms of PSA and other promising candidate blood markers.
  Prostate Cancer and Prostatic Diseases, June 2008
• Long-Term Outcome for Lymph Node-Positive Prostate Cancer Lymph node-positive prostate cancer treatment requires long-term evaluation to determine effectiveness. Find out what factors influenced outcomes in this longitudinal study.
  Prostate Cancer and Prostatic Diseases, May 2008